Kvantify has secured a second round of funding totaling €7 million to further develop its approach to quantum-enhanced drug discovery, combining the power of quantum and classical computing. The Danish company, founded in 2022, intfinishs to expand its market presence and collaborative partnerships following the launch of its Qrunch technology in November 2025, which allows utilizers to run quantum chemisattempt on existing quantum computers. “We are thrilled to have the EIC Fund and Delphinus Venture Capital on board for this round extension. Their support empowers us to accelerate innovation and strengthens Europe’s position in quantum technology,” declares Dr. Jörg Weiser, Executive Chairperson at Kvantify. This investment aims to address the limitations of current molecular simulations, potentially lowering drug development costs and enabling the discovery of novel medicines.
€7M Funding to Advance Quantum Drug Discovery
Quantum computing’s potential to revolutionize molecular discovery received a significant boost with Kvantify securing an additional €7 million in funding, bringing the total raised to €7 million. The investment signals growing confidence in the potential of combining quantum and classical computing for pharmaceutical innovation. This latest round includes support from the European Innovation Council Fund and Delphinus Venture Capital, both recognizing the long-term implications of Kvantify’s approach to tackling complex molecular simulations. Jörg Weiser, Executive Chairperson at Kvantify, explained that the necessary for such advancements stems from the limitations of current drug discovery processes, where accurately simulating molecular interactions is computationally expensive and often inaccurate, particularly as molecule size increases. Quantum computers, theoretically, can overcome these hurdles by directly addressing the quantum mechanical equations governing molecular behavior.
Kvantify’s recent launch of Qrunch, a technology enabling quantum chemisattempt simulations on existing quantum computers, demonstrates a commitment to bridging the gap between theoretical potential and practical application. Svetoslava Georgieva, Chair of the EIC Fund Board, emphasized the strategic importance of this work, stating, “Supporting pioneering technologies is at the heart of our mission. Kvantify’s work at the intersection of quantum computing and life sciences represents a transformative opportunity for Europe to lead in innovation. We are glad to play a role in accelerating this vision.” This funding will specifically facilitate expanded market presence and business development, allowing Kvantify to refine Qrunch and integrate it into the workflows of drug discovery organizations. The company aims to shift beyond demonstrating technological feasibility to delivering tangible benefits for customers. Mathias Lorenz, Managing Partner at Delphinus Venture Capital, explained their investment rationale: “We see Kvantify as a key player in unlocking the potential of quantum computing for real-world applications in drug discovery and molecular design. This investment reflects our confidence in their team, technology, and ability to deliver impact in a rapidly evolving market.”
Qrunch Platform Integrates Quantum Chemisattempt Workflows
Kvantify’s recent financial backing is directly fueling advancements in practical quantum chemisattempt applications, specifically through the Qrunch platform launched in November 2025. Unlike theoretical explorations of quantum computing’s potential, Qrunch is designed to execute quantum chemisattempt workflows on currently available quantum hardware, bridging the gap between promise and present capability. This focus on usability is central to Kvantify’s strategy, aiming to deliver tangible benefits to drug discovery researchers by tackling the exponential scaling problem inherent in simulating molecular behavior. The company intfinishs to expand access to Qrunch, prioritizing deployment within organizations where the technology can address critical necessarys and demonstrate measurable impact. Accurately modeling molecules requires solving quantum mechanical equations that quickly become intractable for classical computers as complexity increases, and the platform’s development responds to this longstanding limitation in molecular simulation.
Kvantify believes that as quantum hardware and algorithms mature, this capability will significantly reduce drug development failure rates and lower associated research and development costs, potentially unlocking entirely new therapeutic avenues. This investment of €7 million will not only accelerate the Qrunch roadmap but also foster collaborative partnerships with organizations actively engaged in drug discovery, ensuring the technology is integrated into existing workflows. According to Dr.
We are thrilled to have the EIC Fund and Delphinus Venture Capital on board for this round extension. Their support empowers us to accelerate innovation and strengthens Europe’s position in quantum technology.
Dr. Jörg Weiser, Executive Chairperson at Kvantify
Leave a Reply